ROR1 Emerges in Mantle-Cell Relapse After CD19 CAR-T

Company MD Anderson Cancer Center Event Type Publication / Peer-Reviewed Study Modality ROR1/CD3 T-Cell Engager Asset Experimental ROR1-Directed Bispecific Construct Target ROR1 / CD3 Disease Area Mantle-Cell Lymphoma (Post-CAR-T Relapse) Summary A peer-reviewed Leukemia letter reports increased ROR1 expression in mantle-cell lymphoma specimens after CD19…